Ipsen Press Releases | Latest News & Updates

Topics

Period

Filter by

Reset

Showing: 1 – 05 of 240 Press Releases

Show

Sort

03 April 2026

03 April 2026

Download Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer

Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer

18 March 2026

18 March 2026

Download Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR

Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR

12 March 2026

12 March 2026

Download Ipsen appoints Michelle C. Werner as EVP, President of North America

Ipsen appoints Michelle C. Werner as EVP, President of North America

09 March 2026

09 March 2026

Download Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma

Notice of Epizyme, Inc. voluntary product recall for Tazemetostat Hydrobromide Tablets (Tazverik®)

27 February 2026

27 February 2026

$Download Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma$

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma

Your dedicated contacts

Sally Bain

Head of Global Media Relations

+1 857 320 0517

sally.bain@ipsen.com

Anne Liontas

France Media Relations

+33 7 67 34 72 96

anne.liontas.ext@ipsen.com

Stay updated

Register to receive our latest news